Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression

Authors: Mehtap S Gündogdu, He Liu, Daniela Metzdorf, Dagmar Hildebrand, Michael Aigner, Klaus Aktories, Klaus Heeg, Katharina F Kubatzky

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

RhoH is a constitutively active member of the family of Rho GTPases. Its expression is restricted to the haematopoietic lineage, where it serves as a positive regulator for T cell selection and mast cell function and as a negative regulator for growth-related functions in other lineages. Here, we examined the activation of signal transducer and activator of transcription (STAT) proteins in response to stimulation with interleukin 3 (IL3).

Results

Using the murine IL3-dependent cell line BaF3 we investigated the influence of RhoH protein expression levels on IL3-mediated cellular responses. RhoH overexpressing cells showed lower sensitivity to IL3 and decreased STAT5 activation. SiRNA-mediated repression of RhoH gene expression led to an increase in proliferation and STAT5 activity which correlated with an increased number of IL3 receptor α chain molecules, also known as CD123, expressed at the cell surface. Interestingly, these findings could be reproduced using human THP-1 cells as a model system for acute myeloid leukaemia, where low RhoH levels are known to be an unfavourable prognostic marker. Overexpression of RhoH on the other hand caused an induction of STAT1 activity and western blot analysis revealed that activated STAT1 is phosphorylated on Tyr701. STAT1 is known to induce apoptosis or cell cycle arrest and we detected an upregulation of cyclin-dependent kinase inhibitors (CDKI) p21 Cip1 and p27 Kip1 in RhoH overexpressing BaF3 cells.

Conclusions

We propose that RhoH functions as a negative regulator for IL3-induced signals through modulation of the JAK-STAT pathway. High levels of RhoH allow the IL3-dependent activation of STAT1 causing decreased proliferation through upregulation of p21 Cip1 and p27 Kip1 . Low RhoH levels on the other hand led to an upregulation of IL3-dependent cell growth, STAT5 activity and an increase of CD123 surface expression, linking RhoH to a CD123/STAT5 phenotype that has been described in AML patients.
Appendix
Available only for authorised users
Literature
1.
Madaule P, Axel R: A novel ras-related gene family. Cell. 1985, 41: 31-40. 10.1016/0092-8674(85)90058-3CrossRefPubMed
2.
Bar-Sagi D, Hall A: Ras and Rho GTPases: a family reunion. Cell. 2000, 103: 227-238. 10.1016/S0092-8674(00)00115-XCrossRefPubMed
3.
Vojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998, 273: 19925-19928. 10.1074/jbc.273.32.19925CrossRefPubMed
4.
Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature. 2002, 420: 629-635. 10.1038/nature01148CrossRefPubMed
5.
Dallery E, Galiegue-Zouitina S, Collyn-d'Hooghe M, Quief S, Denis C, Hildebrand MP, Lantoine D, Deweindt C, Tilly H, Bastard C: TTF, a gene encoding a novel small G protein, fuses to the lymphoma-associated LAZ3 gene by t(3;4) chromosomal translocation. Oncogene. 1995, 10: 2171-2178.PubMed
6.
Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R: rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem. 1989, 264: 16378-16382.PubMed
7.
Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B: The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function. Mol Cell Biol. 2002, 22: 1158-1171. 10.1128/MCB.22.4.1158-1171.2002PubMedCentralCrossRefPubMed
8.
Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ: Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene. 1998, 17: 1415-1438. 10.1038/sj.onc.1202181CrossRefPubMed
9.
Gu Y, Chae HD, Siefring JE, Jasti AC, Hildeman DA, Williams DA: RhoH GTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat Immunol. 2006, 7: 1182-1190. 10.1038/ni1396CrossRefPubMed
10.
11.
Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001, 412: 341-346. 10.1038/35085588CrossRefPubMed
12.
Galiegue-Zouitina S, Delestre L, Dupont C, Troussard X, Shelley CS: Underexpression of RhoH in Hairy Cell Leukemia. Cancer Res. 2008, 68: 4531-4540. 10.1158/0008-5472.CAN-07-5661CrossRefPubMed
13.
Iwasaki T, Katsumi A, Kiyoi H, Tanizaki R, Ishikawa Y, Ozeki K, Kobayashi M, Abe A, Matsushita T, Watanabe T: Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Eur J Haematol. 2008, 81: 454-460. 10.1111/j.1600-0609.2008.01132.xCrossRefPubMed
14.
Gu Y, Jasti AC, Jansen M, Siefring JE: RhoH, a hematopoietic-specific Rho GTPase, regulates proliferation, survival, migration, and engraftment of hematopoietic progenitor cells. Blood. 2005, 105: 1467-1475. 10.1182/blood-2004-04-1604CrossRefPubMed
15.
Chae HD, Lee KE, Williams DA, Gu Y: Cross-talk between RhoH and Rac1 in regulation of actin cytoskeleton and chemotaxis of hematopoietic progenitor cells. Blood. 2008, 111: 2597-2605. 10.1182/blood-2007-06-093237PubMedCentralCrossRefPubMed
16.
Dorn T, Kuhn U, Bungartz G, Stiller S, Bauer M, Ellwart J, Peters T, Scharffetter-Kochanek K, Semmrich M, Laschinger M: RhoH is important for positive thymocyte selection and T-cell receptor signaling. Blood. 2007, 109: 2346-2355. 10.1182/blood-2006-04-019034CrossRefPubMed
17.
Daryadel A, Yousefi S, Troi D, Schmid I, Schmidt-Mende J, Mordasini C, Dahinden CA, Ziemiecki A, Simon HU: RhoH/TTF negatively regulates leukotriene production in neutrophils. J Immunol. 2009, 182: 6527-6532. 10.4049/jimmunol.0803846CrossRefPubMed
18.
Oda H, Fujimoto M, Patrick MS, Chida D, Sato Y, Azuma Y, Aoki H, Abe T, Suzuki H, Shirai M: RhoH plays critical roles in Fc epsilon RI-dependent signal transduction in mast cells. J Immunol. 2009, 182: 957-962.CrossRefPubMed
19.
Yousefi S, Cooper PR, Mueck B, Potter SL, Jarai G: cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem Biophys Res Commun. 2000, 277: 401-409. 10.1006/bbrc.2000.3678CrossRefPubMed
20.
Migliaccio G, Migliaccio AR, Visser JW: Synergism between erythropoietin and interleukin-3 in the induction of hematopoietic stem cell proliferation and erythroid burst colony formation. Blood. 1988, 72: 944-951.PubMed
21.
Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ: Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. 1998, 392: 90-93. 10.1038/32190CrossRefPubMed
22.
Rodewald HR, Dessing M, Dvorak AM, Galli SJ: Identification of a committed precursor for the mast cell lineage. Science. 1996, 271: 818-822. 10.1126/science.271.5250.818CrossRefPubMed
23.
Liu X, Constantinescu SN, Sun Y, Bogan JS, Hirsch D, Weinberg RA, Lodish HF: Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem. 2000, 280: 20-28. 10.1006/abio.2000.4478CrossRefPubMed
24.
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996, 272: 719-722. 10.1126/science.272.5262.719CrossRefPubMed
25.
Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 1995, 14: 1166-1175.PubMedCentralPubMed
26.
Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, Miyajima A, Griffin JD, Ihle JN: JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994, 14: 4335-4341.PubMedCentralCrossRefPubMed
27.
Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996, 15: 2425-2433.PubMedCentralPubMed
28.
Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, Latagliata R, Mariani G, Rossini A, Battistini A: Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002, 100: 2980-2988. 10.1182/blood-2002-03-0852CrossRefPubMed
29.
Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT: Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001, 97: 2177-2179. 10.1182/blood.V97.7.2177CrossRefPubMed
30.
Tian SS, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P: Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood. 1996, 88: 4435-4444.PubMed
31.
Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE: Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996, 93: 7673-7678. 10.1073/pnas.93.15.7673PubMedCentralCrossRefPubMed
32.
Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996, 84: 443-450. 10.1016/S0092-8674(00)81289-1CrossRefPubMed
33.
Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996, 84: 431-442. 10.1016/S0092-8674(00)81288-XCrossRefPubMed
34.
Parada Y, Banerji L, Glassford J, Lea NC, Collado M, Rivas C, Lewis JL, Gordon MY, Thomas NS, Lam EW: BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 2001, 276: 23572-23580. 10.1074/jbc.M101885200CrossRefPubMed
35.
Akala OO, Clarke MF: Hematopoietic stem cell self-renewal. Curr Opin Genet Dev. 2006, 16: 496-501. 10.1016/j.gde.2006.08.011CrossRefPubMed
36.
Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000, 19: 2496-2504. 10.1038/sj.onc.1203486CrossRefPubMed
37.
Karasuyama H, Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988, 18: 97-104. 10.1002/eji.1830180115CrossRefPubMed
38.
Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN: Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem. 2005, 280: 14844-14854. 10.1074/jbc.M411251200CrossRefPubMed
Metadata
Title
The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression
Authors
Mehtap S Gündogdu
He Liu
Daniela Metzdorf
Dagmar Hildebrand
Michael Aigner
Klaus Aktories
Klaus Heeg
Katharina F Kubatzky
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-225

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma

Research

Cyclin K and cyclin D1b are oncogenic in myeloma cells

Research

EGFR isoforms and gene regulation in human endometrial cancer cells

Research

The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells

Research

Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells

Research

VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits